Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 303-317
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.303
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.303
Characteristic | N = 431 | n/N (missing %) |
Age (yr) | 65 (60, 75) | 43 / 43 (0%) |
Sex | 43 / 43 (0%) | |
Female | 13 (30%) | |
Male | 30 (70%) | |
Stage | 43 / 43 (0%) | |
I | 11 (26%) | |
II | 10 (23%) | |
III | 8 (19%) | |
IV | 14 (33%) | |
Grade | 43 / 43 (0%) | |
G1 | 1 (2.3%) | |
G2 | 10 (23%) | |
G3 | 31 (72%) | |
Gx | 1 (2.3%) | |
Tumour location | 43 / 43 (0%) | |
Distal | 14 (33%) | |
Proximal | 26 (60%) | |
Whole stomach | 3 (7.0%) | |
Lauren classification | 41 / 43 (4.7%) | |
Diffuse | 26 (63%) | |
Intestinal | 13 (32%) | |
Mixed | 2 (4.9%) | |
Signet ring cell (present) | 26 (63%) | 41 / 43 (4.7%) |
H. pylori history | 32 / 43 (26%) | |
Negative | 22 (69%) | |
Positive | 9 (28%) | |
Treated | 1 (3.1%) | |
Smoker | 40 / 43 (7.0%) | |
Yes | 9 (22%) | |
No | 14 (35%) | |
Ex | 17 (42%) | |
Smoker (pack years) | 7 (0, 32) | 39 / 43 (9.3%) |
Surgery | 43 / 43 (0%) | |
Total gastrectomy | 20 (47%) | |
Distal gastrectomy | 14 (33%) | |
No resection | 9 (21%) | |
Neoadjuvant chemotherapy | 18 (42%) | 43 / 43 (0%) |
CD4/CD8 ratio (% positive) | 1.7 (1.2, 2.8) | 42 / 43 (2.3%) |
CD4 (% positive) | 14 (7, 24) | 43 / 43 (0%) |
CD8 (% positive) | 8 (5, 11) | 42 / 43 (2.3%) |
Galectin-3 (% positive) | 46 (30, 57) | 43 / 43 (0%) |
E-cadherin (% positive) | 18 (6, 28) | 43 / 43 (0%) |
E-cadherin H-score | 22 (7, 40) | 43 / 43 (0%) |
Characteristic | Incomplete response, N = 141 | Response, N = 41 | P value2 |
Age (yr) | 60 (57, 63) | 60 (52, 67) | > 0.9 |
Sex | 0.3 | ||
F | 5 (36%) | 0 (0%) | |
M | 9 (64%) | 4 (100%) | |
Stage | 0.6 | ||
I | 2 (14%) | 2 (50%) | |
II | 5 (36%) | 1 (25%) | |
III | 6 (43%) | 1 (25%) | |
IV | 1 (7.1%) | 0 (0%) | |
Grade | 0.6 | ||
G1 | 1 (7.1%) | 0 (0%) | |
G2 | 2 (14%) | 2 (50%) | |
G3 | 10 (71%) | 2 (50%) | |
Gx | 1 (7.1%) | 0 (0%) | |
Tumour location | > 0.9 | ||
Distal | 3 (21%) | 1 (25%) | |
Proximal | 10 (71%) | 3 (75%) | |
Whole stomach | 1 (7.1%) | 0 (0%) | |
Lauren classification | 0.5 | ||
Diffuse | 10 (71%) | 1 (33%) | |
Intestinal | 4 (29%) | 2 (67%) | |
Signet ring cell (present) | 9 (64%) | 1 (33%) | 0.5 |
H. pylori history | > 0.9 | ||
Negative | 8 (57%) | 2 (50%) | |
Positive | 3 (21%) | 1 (25%) | |
Unknown | 3 (21%) | 1 (25%) | |
Smoker | > 0.9 | ||
Yes | 4 (33%) | 2 (50%) | |
No | 4 (33%) | 1 (25%) | |
Ex | 4 (33%) | 1 (25%) | |
Smoker (pack years) | 13 (0, 40) | 36 (25, 42) | 0.5 |
Surgery | > 0.9 | ||
Total gastrectomy | 10 (71%) | 3 (75%) | |
Distal gastrectomy | 3 (21%) | 1 (25%) | |
No resection | 1 (7.1%) | 0 (0%) |
- Citation: Skubleny D, Lin A, Garg S, McLean R, McCall M, Ghosh S, Spratlin JL, Schiller D, Rayat G. Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. World J Gastrointest Oncol 2023; 15(2): 303-317
- URL: https://www.wjgnet.com/1948-5204/full/v15/i2/303.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i2.303